FDA Accepts Libtayo® (cemiplimab-rwlc) for Priority Review for Advanced Cervical Cancer

TARRYTOWN, N.Y. , Sept. 28, 2021 /PRNewswire/ — European Union regulatory submission planned by end of 2021 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License

close

Get every new post delivered right to your inbox.

Original Source